AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37172934 — intervention group
Group type: EXPERIMENTAL
Intervention: Occurrence of significant complications
Number of subjects: 203
Study 37172938 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-second rule for high confidence assignment
Number of subjects: 1793
Study 37172938 — intervention group
Group type: COMPARATOR
Intervention: Standard real-time optical diagnosis
Number of subjects: 1793
Study 37172969 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant intratumoral influenza vaccine treatment
Number of subjects: 10
Study 37172969 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 10
Study 37173074 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic cough (CC)
Number of subjects: 1183
Study 37173074 — intervention group
Group type: EXPERIMENTAL
Intervention: CT imaging parameters (total airway count, airway wall thickness, emphysema)
Number of subjects: 1183
Study 37173074 — intervention group
Group type: EXPERIMENTAL
Intervention: CT parameters and CC
Number of subjects: 1183
Study 37173099 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine-learning-based risk score for net adverse clinical events (NACE) developed using random survival forest (RSF) and Cox regression models.
Number of subjects: 2215
Study 37173099 — intervention group
Group type: EXPERIMENTAL
Intervention: Integer-based risk score for NACE.
Number of subjects: 2215
Study 37173099 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision curve analysis of the risk score.
Number of subjects: 2215
Study 37173113 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental enrichment (EE) intervention consisting of six 40-min sessions over 9 days, including mindfulness in multisensory VR and indoor cycling with cognitive training.
Number of subjects: 135
Study 37173113 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving standard management for AUD.
Number of subjects: 135
Study 37173113 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental enrichment (EE) intervention.
Number of subjects: 135
Study 37173116 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg once daily for 7 days
Number of subjects: 0
Study 37173116 — intervention group
Group type: COMPARATOR
Intervention: No additional postprocedural anticoagulation
Number of subjects: 0
Study 37173129 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab treatment
Number of subjects: 0
Study 37173129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37173129 — intervention group
Group type: COMPARATOR
Intervention: Interferon beta
Number of subjects: 0
Study 37173224 — intervention group
Group type: EXPERIMENTAL
Intervention: Bispecific antibodies and other emerging treatment strategies
Number of subjects: 0
Study 37173291 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized vestibular retraining therapy; 12 twice-weekly sessions.
Number of subjects: 13
Study 37173355 — intervention group
Group type: EXPERIMENTAL
Intervention: St. George's Respiratory Questionnaire (SGRQ)
Number of subjects: 112
Study 37173355 — intervention group
Group type: EXPERIMENTAL
Intervention: Euroquol-5D-5L (EQ-5D-5L)
Number of subjects: 112
Study 37173355 — intervention group
Group type: EXPERIMENTAL
Intervention: Short form 36 (SF-36)
Number of subjects: 112
Study 37173365 — intervention group
Group type: EXPERIMENTAL
Intervention: OBI-3424 administered intravenously at doses of 1, 2, 4, 6, 8, or 12 mg/m
Number of subjects: 0
Study 37173365 — intervention group
Group type: EXPERIMENTAL
Intervention: OBI-3424 at 12 mg/m
Number of subjects: 0
Study 37173512 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal esketamine treatment during induction phase (twice-weekly)
Number of subjects: 1148
Study 37173512 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal esketamine treatment during optimization/maintenance phase (individualized dosing)
Number of subjects: 1148
Study 37173512 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term treatment with esketamine (up to 4.5 years)
Number of subjects: 1148
Study 37173568 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Shiatsu treatment
Number of subjects: 120
Study 37173568 — intervention group
Group type: COMPARATOR
Intervention: Sham Shiatsu treatment
Number of subjects: 120
Study 37173690 — intervention group
Group type: EXPERIMENTAL
Intervention: Polish version of the Alberta Infant Motor Scale (AIMS)
Number of subjects: 431
Study 37173701 — intervention group
Group type: EXPERIMENTAL
Intervention: Male participants
Number of subjects: 200
Study 37173701 — intervention group
Group type: EXPERIMENTAL
Intervention: Female participants
Number of subjects: 200
Study 37173701 — intervention group
Group type: COMPARATOR
Intervention: Both sexes
Number of subjects: 200
Study 37173715 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclavian vein catheterisation
Number of subjects: 100
Study 37173715 — intervention group
Group type: COMPARATOR
Intervention: Internal jugular vein catheterisation
Number of subjects: 100
Study 37173764 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous online delivered exercise maintenance classes with health coaching calls
Number of subjects: 40
Study 37173764 — intervention group
Group type: COMPARATOR
Intervention: Synchronous online delivered exercise maintenance classes without health coaching calls
Number of subjects: 40
Study 37173784 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline 10 mg/kg/12h IV for 4 weeks plus supportive measures
Number of subjects: 80
Study 37173784 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus supportive measures
Number of subjects: 80
Study 37173784 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline treatment
Number of subjects: 80
Study 37173791 — intervention group
Group type: EXPERIMENTAL
Intervention: CT1812
Number of subjects: 0
Study 37173791 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study 37173792 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation Treatment for Cardiac Smokers (BAT-CS)
Number of subjects: 324
Study 37173792 — intervention group
Group type: COMPARATOR
Intervention: Control (smoking cessation and general health education)
Number of subjects: 324
Study 37173799 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoke-Free Home SafeCare (SFH-SC)
Number of subjects: 8
Study 37173865 — intervention group
Group type: EXPERIMENTAL
Intervention: Meaning-Centered Pain Coping Skills Training (MCPC)
Number of subjects: 60
Study 37173865 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study 37174154 — intervention group
Group type: EXPERIMENTAL
Intervention: Radon app for smartphones
Number of subjects: 116
Study 37174154 — intervention group
Group type: COMPARATOR
Intervention: Printed brochures
Number of subjects: 116
Study 37174643 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine
Number of subjects: 90
Study 37174643 — intervention group
Group type: COMPARATOR
Intervention: Control (platform immunotherapy)
Number of subjects: 90
Study 37174650 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic formula containing three bifidobacteria; details on dosage and duration not provided.
Number of subjects: 0
Study 37174706 — intervention group
Group type: EXPERIMENTAL
Intervention: CTLA-4 immune checkpoint inhibition (tremelimumab) combined with radiotherapy (RT)
Number of subjects: 0
Study 37174706 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT) with CTLA-4 immune checkpoint inhibition (ICI)
Number of subjects: 0
Study 37174730 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (Vit C)
Number of subjects: 131
Study 37174730 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (Vit E)
Number of subjects: 131
Study 37174730 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 131
Study 37174730 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (MT)
Number of subjects: 131
Study 37174730 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 131
Study 37174733 — intervention group
Group type: EXPERIMENTAL
Intervention: Spot urine proteinuria measurement
Number of subjects: 47
Study 37174733 — intervention group
Group type: EXPERIMENTAL
Intervention: Spot urine albuminuria measurement
Number of subjects: 47
Study 37174969 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound examination of the larynx and trachea
Number of subjects: 300
Study 37175874 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab (10 mg/kg intravenously every 3 weeks × two doses)
Number of subjects: 0
Study 37178136 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended ablation group (clinical arrhythmia plus substrate-based ablation)
Number of subjects: 77
Study 37178136 — intervention group
Group type: COMPARATOR
Intervention: Limited ablation group (clinical arrhythmia ablation only)
Number of subjects: 77
Study 37178149 — intervention group
Group type: EXPERIMENTAL
Intervention: Right median nerve electrical stimulation (RMNS) - 20 mA, 300 μs, 40 Hz stimulation pulses, lasting 20 s per minute, 8 h per day, for 2 weeks.
Number of subjects: 329
Study 37178149 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (control group)
Number of subjects: 329
Study 37178149 — intervention group
Group type: EXPERIMENTAL
Intervention: RMNS group
Number of subjects: 329
Study 37178160 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-fast fluorescence confocal microscopy imaging
Number of subjects: 181
Study 37178160 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program composed of 110 images divided into nine learning sessions
Number of subjects: 181
Study 37178435 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Semaglutide
Number of subjects: 4
Study 37178435 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous Semaglutide
Number of subjects: 4
Study 37178442 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of small ONH
Number of subjects: 200
Study 37178442 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of ONH tilt
Number of subjects: 200
Study 37178442 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of LC defects
Number of subjects: 200
Study 37178442 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of LC defects and thicker LC
Number of subjects: 200
Study 37178442 — intervention group
Group type: EXPERIMENTAL
Intervention: Axial length > 28 mm
Number of subjects: 200
Study 37178517 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygenic risk scores (PRS) for neuroticism
Number of subjects: 0
Study 37178517 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral and cognitive variables (fear, interoceptive, reward, cognitive variables)
Number of subjects: 0
Study 37178517 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning ensemble method
Number of subjects: 0
Study 37178517 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional and interoceptive processing targeting
Number of subjects: 0
Study 37178647 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib 18 mg/m²/d
Number of subjects: 56
Study 37178647 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib 23 mg/m²/d
Number of subjects: 56
Study 37178647 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 56
Study 37178702 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular testing-guided therapy (first-line treatment)
Number of subjects: 880
Study 37178702 — intervention group
Group type: COMPARATOR
Intervention: Susceptibility testing-guided therapy (first-line treatment)
Number of subjects: 880
Study 37178702 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular testing-guided therapy (third-line treatment)
Number of subjects: 880
Study 37178702 — intervention group
Group type: COMPARATOR
Intervention: Susceptibility testing-guided therapy (third-line treatment)
Number of subjects: 880
Study 37178706 — intervention group
Group type: EXPERIMENTAL
Intervention: nOPV2 only
Number of subjects: 736
Study 37178706 — intervention group
Group type: EXPERIMENTAL
Intervention: nOPV2 plus bOPV
Number of subjects: 736
Study 37178706 — intervention group
Group type: COMPARATOR
Intervention: bOPV only
Number of subjects: 736
Study 37178932 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-weekly (BIW) focal boosted prostate SBRT delivering 35 Gy in 5 fractions with an iso-toxic boost up to 50 Gy
Number of subjects: 124
Study 37178932 — intervention group
Group type: COMPARATOR
Intervention: Once-weekly (QW) focal boosted prostate SBRT
Number of subjects: 124
Study 37178978 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated fatty acid (SFA) density
Number of subjects: 81894
Study 37178978 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acid (PUFA) density
Number of subjects: 81894
Study 37178978 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher SFA and PUFA diets
Number of subjects: 81894
Study 37179240 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide plus ADT
Number of subjects: 927
Study 37179240 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus ADT
Number of subjects: 927
Study 37179297 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP plus omega-3 PUFAs (EPA and DHA)
Number of subjects: 40
Study 37179297 — intervention group
Group type: COMPARATOR
Intervention: SRP alone (Control)
Number of subjects: 40
Study 37179349 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyronaridine-artesunate (PA)
Number of subjects: 172
Study 37179349 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 172
Study 37179349 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PA and AL
Number of subjects: 172
Study 37179415 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week home-based physical activity intervention aiming to increase daily steps by 2000 from baseline
Number of subjects: 120
Study 37179415 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week home-based physical activity intervention
Number of subjects: 120
Study 37179438 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients sleeping ≥9 h
Number of subjects: 1175
Study 37179438 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients sleeping ≤5 h
Number of subjects: 1175
Study 37179458 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver-delivered cognitive stimulation therapy (CDCST) for 15 weeks
Number of subjects: 241
Study 37179458 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 241
Study 37179458 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver-delivered cognitive stimulation therapy (CDCST)
Number of subjects: 241
Study 37179526 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-fraction stereotactic ablative body radiotherapy
Number of subjects: 0
Study 37179526 — intervention group
Group type: COMPARATOR
Intervention: Multifraction stereotactic ablative body radiotherapy
Number of subjects: 0
Study 37179530 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal mechanical stimulation therapy (M-Stim) with three vibration motors (50 Hz, 100 Hz, 200 Hz) and amplitudes between 0.1-0.3 m/s for 20 minutes.
Number of subjects: 20
Study 37179555 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural spinal cord stimulation (ESCS)
Number of subjects: 3
Study 37179566 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cerebellar tACS
Number of subjects: 164
Study 37179566 — intervention group
Group type: COMPARATOR
Intervention: Sham cerebellar tACS
Number of subjects: 164
Study 37179746 — intervention group
Group type: EXPERIMENTAL
Intervention: SAT-008 digital device
Number of subjects: 32
Study 37179746 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 32
Study 37179936 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning predicted structural progression based on baseline s-scores
Number of subjects: 237
Study 37179936 — intervention group
Group type: EXPERIMENTAL
Intervention: Kellgren-Lawrence (KL) grades
Number of subjects: 237
Study 37179936 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiographic measurements (JSW, subchondral bone density, osteophytes)
Number of subjects: 237
Study 37179936 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI quantitative measurements (cartilage thickness)
Number of subjects: 237
Study 37179936 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiographic osteophyte size
Number of subjects: 237
Study 37179936 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall structural progression
Number of subjects: 237
Study 37180085 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotenoid intake screener
Number of subjects: 0
Study 37180209 — intervention group
Group type: EXPERIMENTAL
Intervention: Gilteritinib (XOSPATA®)
Number of subjects: 17
Study 37180228 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose (synbiotic) for 12 weeks
Number of subjects: 0
Study 37180228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37180228 — intervention group
Group type: COMPARATOR
Intervention: NIP group (no intervention)
Number of subjects: 0
Study 37180228 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic
Number of subjects: 0
Study 37180415 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQoL) assessment using the Pediatric Quality of Life Inventory (PedsQL)
Number of subjects: 36
Study 37180415 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQoL) assessment
Number of subjects: 36
Study 37180427 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37180469 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram based on multivariate logistic regression
Number of subjects: 2631
Study 37180469 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 2631
Study 37180469 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasgow Coma Scale score
Number of subjects: 2631
Study 37180469 — intervention group
Group type: EXPERIMENTAL
Intervention: Injury Severity Score
Number of subjects: 2631
Study 37180469 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal pupil status
Number of subjects: 2631
Study 37180469 — intervention group
Group type: EXPERIMENTAL
Intervention: Midline shift
Number of subjects: 2631
Study 37180469 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-hospital intubation
Number of subjects: 2631
Study 37180485 — intervention group
Group type: EXPERIMENTAL
Intervention: Macadamia nuts (~15% of daily calories) for 8 weeks
Number of subjects: 35
Study 37180485 — intervention group
Group type: COMPARATOR
Intervention: Usual diet without nuts for 8 weeks (Control)
Number of subjects: 35
Study 37180499 — intervention group
Group type: EXPERIMENTAL
Intervention: Height-adjusted total kidney volume (htTKV) on MRI
Number of subjects: 84
Study 37180505 — intervention group
Group type: EXPERIMENTAL
Intervention: Iptacopan 200 mg twice daily for 24 months
Number of subjects: 450
Study 37180505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study 37180506 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparsentan
Number of subjects: 404
Study 37180506 — intervention group
Group type: COMPARATOR
Intervention: Irbesartan (active control)
Number of subjects: 404
Study 37180745 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intersectional stigma coping intervention (three weekly 2-h group sessions)
Number of subjects: 100
Study 37180745 — intervention group
Group type: COMPARATOR
Intervention: Usual services only (control)
Number of subjects: 100
Study 37180808 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse T and Protrusion (rTAP)
Number of subjects: 52
Study 37180808 — intervention group
Group type: COMPARATOR
Intervention: Double-kissing and crush (DKC)
Number of subjects: 52
Study 37180814 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrysof® IQ Vivity® IOL
Number of subjects: 30
Study 37180843 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily
Number of subjects: 276
Study 37180843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study 37181036 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term rapid severe hypothyroidism induced by thyroid hormone withdrawal
Number of subjects: 75
Study 37181036 — intervention group
Group type: COMPARATOR
Intervention: Euthyroid state before thyroidectomy
Number of subjects: 75
Study 37181123 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling on healthy eating practices for 1 year postpartum
Number of subjects: 0
Study 37181123 — intervention group
Group type: COMPARATOR
Intervention: No counseling (Control)
Number of subjects: 0
Study 37181130 — intervention group
Group type: EXPERIMENTAL
Intervention: Puerto Rican Optimized Mediterranean-like Diet (PROMED) intervention group received 1 individual nutritional counseling session on a portion-control culturally-tailored MedDiet, daily text messages for 2 months, and supplied legumes and vegetable oils.
Number of subjects: 50
Study 37181130 — intervention group
Group type: COMPARATOR
Intervention: Control group received cooking utensils and one standard portion-control nutritional counseling session reinforced with daily texts for 2 months.
Number of subjects: 50
Study 37181156 — intervention group
Group type: EXPERIMENTAL
Intervention: High fiber (∼38 g/d) plant-based diet
Number of subjects: 100
Study 37181156 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of inulin-type fructans (ITF) to the plant-based diet
Number of subjects: 100
Study 37181388 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel monotherapy
Number of subjects: 0
Study 37181388 — intervention group
Group type: COMPARATOR
Intervention: Aspirin monotherapy
Number of subjects: 0
Study 37181420 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% cream as maintenance therapy after baseline therapy with topical glucocorticoids (group 1)
Number of subjects: 108
Study 37181420 — intervention group
Group type: COMPARATOR
Intervention: Topical glucocorticoids without subsequent use of pimecrolimus (group 2)
Number of subjects: 108
Study 37181803 — intervention group
Group type: EXPERIMENTAL
Intervention: Fit-metabolic syndrome (14.4%)
Number of subjects: 492
Study 37181803 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfit-metabolic syndrome (36.2%)
Number of subjects: 492
Study 37181803 — intervention group
Group type: EXPERIMENTAL
Intervention: Fit-dysmetabolism (not specified percentage)
Number of subjects: 492
Study 37181803 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfit-dysmetabolism (not specified percentage)
Number of subjects: 492